Personalised Multicomponent Exercise Programme in Peripheral Arterial Disease
Launched by UNIVERSITY OF TRÁS-OS-MONTES AND ALTO DOURO · May 7, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new personalized exercise program for people with peripheral arterial disease (PAD), which is a condition that reduces blood flow to the legs and can cause pain, cramps, or discomfort when walking. The goal is to create a tailored exercise plan that includes both cardiovascular and resistance training. By using technology to monitor how each patient responds to exercise in real-time, the researchers hope to improve individual treatment and help patients walk better and feel less pain.
To be eligible for the trial, participants must be diagnosed with stable PAD and experience mild to moderate leg pain when walking. They should also be able to walk on a treadmill and provide written consent to join the study. Importantly, individuals with certain conditions or previous treatments may not be eligible. Participants in this trial can expect to engage in a supervised exercise program that is specifically designed to meet their personal needs, helping them manage their symptoms more effectively.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with clinically stable PAD;
- • An ankle-brachial index (ABI) between 0.41-0.90 at rest in one or both lower limbs;
- • Mild to moderate claudication, corresponding to Fontaine Stage IIa and IIb;
- • A history of ambulatory leg pain;
- • Ambulatory leg pain confirmed by treadmill test;
- • Able to provide written consent.
- Exclusion Criteria:
- • Noncompressible, calcified, tibial arteries (resting ABI ≥ 1.4);
- • Use of medication that could influence claudication (e.g. Cilostazol or Pentoxifylline) 3 months prior to investigation;
- • Previous intervention (e.g. balloon angioplasty, stenting, bypass, exercise programme);
- • Inability to walk on a treadmill at a speed of 3.2 km/h (2 mph);
- • Participation in the past 3 months in a clinical trial or exercise program;
- • Asymptomatic PAD determined from the medical history;
- • Exercise limited by factors other diseases or conditions than intermittent claudication;
- • Angina pectoris, congestive heart failure, chronic obstructive pulmonary disease, severe arthritis, or limb amputation.
About University Of Trás Os Montes And Alto Douro
The University of Trás-os-Montes and Alto Douro (UTAD) is a leading academic institution in Portugal, dedicated to advancing research and education in various fields, including health sciences. With a strong emphasis on innovation and collaboration, UTAD actively engages in clinical trials to explore new therapeutic approaches and improve patient outcomes. The university's commitment to high-quality research is supported by a multidisciplinary team of experts and state-of-the-art facilities, making it a pivotal contributor to the advancement of medical knowledge and public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vila Real, , Portugal
Vila Real, , Portugal
Vila Real, , Portugal
Patients applied
Trial Officials
Catarina Abrantes, Ph.D.
Principal Investigator
University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported